The Cytolytically Inactive Terminal Complement Complex Activates Endothelial Cells to Express Adhesion Molecules and Tissue Factor Procoagulant Activity by Tedesco, Francesco et al.
 
1619
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/97/05/1619/09 $2.00
Volume 185, Number 9, May 5, 1997 1619–1627
 
The Cytolytically Inactive Terminal Complement Complex
Activates Endothelial Cells to Express Adhesion Molecules
and Tissue Factor Procoagulant Activity
 
By Francesco Tedesco,
 
*
 
 Mario Pausa,
 
‡
 
 Ermanno Nardon,
 
*
 
Martino Introna,
 
§
 
 Alberto Mantovani,
 
§
 
i
 
 and Aldo Dobrina
 
*
 
From 
 
*
 
Dipartimento di Fisiologia e Patologia and 
 
‡
 
Istituto di Ginecologia ed Ostetricia, Università
di Trieste, Istituto di Ricovero e Cura a Carattere Scientiﬁco “Burlo Garofolo”, Trieste, Italy; 
 
§
 
Istituto di 
Ricerche Farmacologiche “Mario Negri”, Milan, Italy; and 
 
i
 
Dipartimento di Biotecnologia, Sezione
di Patologia ed Immunologia, Università di Brescia, Brescia, Italy
 
Summary
 
The membrane attack complex of complement (C) in sublytic concentrations stimulates endo-
thelial cells (EC) to express adhesion molecules and to release biologically active products. We
have examined the ability of a cytolytically inactive form of this complex, which is incapable of
inserting into the cell membrane, to upregulate the expression of adhesion molecules and of tis-
sue factor (TF) procoagulant activity. The inactive terminal C complex (iTCC) was prepared
by mixing C5b6, C7, C8, and C9 and was purified by fast protein liquid chromatography on a
Superose 12 column. Binding of this complex to EC was found to be dose dependent and was
inhibited by anti-C9 antibodies, as assessed both by ELISA using an mAb anti-C9 neoantigen
and by measuring cell-bound 
 
125
 
I-labeled iTCC. Exposure of EC to iTCC resulted in a dose-
and time-dependent expression of endothelial leukocyte adhesion molecule 1, intercellular ad-
hesion molecule 1, and vascular cell adhesion molecule 1 accompanied by increased levels of
the corresponding mRNA, but not in the rapid expression of P-selectin. Inactive TCC also in-
duced increased TF activity evaluated by a chromogenic assay that measures the formation of
factor Xa. These effects were inhibited by anti-C9 antibodies. The data support the conclusion
that iTCC may induce proinflammatory and procoagulant activities on EC.
 
E
 
ndothelial cells (EC)
 
1
 
 are continuously exposed to the
action of biologically active products of the comple-
ment (C) system, which are readily available in the circula-
tion after C activation by several stimuli, such as immune
complexes or endotoxin. The major biological effects of
these products on EC is to favor their interaction with cir-
culating leukocytes and to promote migration of these cells
into the inflamed tissue (1). The in vivo relevance of these
C biological activities is supported by the finding that C is
required for the accumulation of neutrophils into the tissue
in a rat model of lung injury caused by intrapulmonary de-
position of immune complexes or systemic C activation by
cobra venom factor (2).
Various C activation products interact with EC and
stimulate the expression of adhesion molecules as well as
the secretion of proinflammatory factors. Thus, C1q linked
to immune complexes binds to C1q receptor on EC stimu-
lating adhesion of leukocytes and expression of E-selectin,
intercellular adhesion molecule (ICAM)-1, and vascular
cell adhesion molecule (VCAM)-1 (3). Similarly, C5a in-
duces expression of P-selectin and increased adhesion of
neutrophils after interaction with the C5a receptor ex-
pressed on EC (4). Also, iC3b molecules deposited on the
membrane of EC bind to their ligand CD11b/CD18 on
PMN and cause rapid neutrophil–endothelial adhesion (5).
In the last few years, various groups have reported data
indicating that the membrane attack complex (MAC) of C,
formed by the assembly of the five terminal C components,
exhibits several biologic effects on EC. These include the
release of prostacyclin PGI
 
2
 
 (6), von Willebrand factor (7),
basic fibroblastic growth factor, platelet-activating factor
(8), IL-8, and monocyte chemotactic protein 1 (9). MAC
has also been shown to stimulate the expression of P-selec-
tin (7) and to potentiate the upregulation of E-selectin and
ICAM-1 induced by TNF-
 
a
 
 (10). These are noncytotoxic
 
1
 
Abbreviations used in this paper:
 
 C, complement; EC, endothelial cells;
ELAM, endothelial leukocyte adhesion molecule; HUVEC, human um-
bilical vein endothelial cells; ICAM, intercellular adhesion molecule; iTCC,
inactive terminal C complex; MAC, membrane attack complex; RT,
room temperature; RT-PCR, reverse transcriptase PCR; SFM, serum-
free medium; TF, tissue factor; VCAM, vascular cell adhesion molecule.
 
A preliminary report of this work was presented in an abstract form at the
XVI International Complement Workshop, Boston, USA, June 16–21,
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effects elicited by sublytic amounts of MAC that inserts into
the plasma membranes of EC without producing overt cy-
tolysis.
The assembly of MAC on EC initiates with the binding
of the C5b-7 complex formed in the fluid phase to the
phospholipid bilayer of the cell membrane followed by ac-
tivation of C8 and C9. However, the insertion of the C5b-9
complex into the cell membrane is prevented by the action
of two serum inhibitors, vitronectin or S protein (11) and
clusterin (12), and also by the rapid decay of the metastable
binding site transiently exposed in the C7 component of
the complex, although the decayed C5b-7 still binds C8 and
C9 forming an inactive terminal C complex (iTCC; 13). The
fate of these inactive complexes and their biological effects
on bystander cells are, to a large extent, unknown. Wang et
al. (14) have recently shown that iC5b67 stimulates PMN
chemotaxis and Ca
 
2
 
1
 
 fluxes, thus extending an original ob-
servation made several years ago by Lachmann et al. (15).
These findings suggest that the inactive complexes may not
be functionally irrelevant.
The purpose of the present study is to examine iTCC for
its ability to interact with EC and to induce biological ef-
fects. Data will be presented indicating that iTCC not only
binds to these cells, but also upregulates the expression of
adhesion molecules and induces tissue factor activity.
 
Materials and Methods
 
Reagents and C Components.
 
Recombinant human IL-1
 
a
 
 (10
 
7
 
U/mg) and TNF-
 
a
 
 (2.0 
 
3
 
 10
 
7
 
 U/mg) were purchased from
Boehringer Mannheim (Milan, Italy) and Bachem Biochemica
GmbH (Heidelberg, Germany), respectively. LPS from 
 
Escheri-
chia coli
 
 O55:B5, human coagulation factor VII, bovine factor X,
BSA, histamine, and 
 
p
 
-nitrophenyl phosphate were obtained from
Sigma Chemical Co. (Milan, Italy). Thromboplastin and S-2765,
the chromogenic substrate for factor Xa, were provided by Chro-
mogenix (Mölndal, Sweden), and the human C components
from C7 to C9 were from Quidel (San Diego, CA).
 
Antibodies.
 
Goat antisera to C5, C6, and C9 were purchased
from Quidel, and goat IgG directed against C8 was obtained from
Atlantic Antibodies (Scarborough, ME). Antisera to C7 and C9 were
raised in goat and rabbit, respectively, by repeated subcutaneous in-
jections of the purified components and their specificity was checked
by ELISA and Western blotting. The IgG were purified from the
antisera by affinity chromatography on protein G–Sepharose column
(Pharmacia Biotech, Milan, Italy). The mAb aE11 recognizing a
neoantigen of poly (C9) (16) was a gift from T.E. Mollnes (Bodo,
Norway). The following mAb to adhesion molecules were used:
anti–endothelial leukocyte adhesion molecule (ELAM)-1 and
anti-P selectin were from Cymbus Bioscience Ltd. (Southampton,
U.K.), and RR1/1 anti–ICAM-1 (17) and 4B9 anti–VCAM-1 (18)
were obtained through the courtesy of R. Rothlein (Boehringer
Ingelheim, Ridgefield, CT) and J. Harlan (University of Wash-
ington, Seattle, WA), respectively. An mAb that recognizes hu-
man tissue factor and neutralizes its procoagulant activity was
provided by American Diagnostica Inc. (Greenwich, CT). Alka-
line phosphatase-labeled affinity-purified antibodies from goat to
mouse IgG were purchased from Sigma Chemical Co.
 
Preparation of C5b6.
 
C5b6 was purified from 300 ml of fresh
frozen human plasma depleted of C7 by immunoaffinity chroma-
tography using cyanogen bromide–activated Sepharose 4B (Pharma-
cia Biotech) coupled with IgG anti-C7. The fractions eluted from
the column were checked for the presence of C5, C6, and C7 by
ELISA after a procedure previously described in detail (19) with a
sensitivity limit of 
 
z
 
1–3 ng/ml. The fractions containing C5 and
C6 at levels comparable to those of the original plasma and unde-
tectable C7 were pooled and recalcified by the addition of 20 mM
CaCl
 
2
 
. The C5b6 complex was purified from yeast-activated C7-
depleted serum essentially as described by Harrison and Lach-
mann (20) with some modifications that included fractionation of
the active material obtained from euglobulin precipitation and
DEAE-Sephacel chromatography through Ultrogel AcA 34 (IBF-
LKB, Milan, Italy) and final purification by gel filtration on Su-
perose 12 using the fast protein liquid chromatography system
(Pharmacia Biotech). The purified C5b6 had a protein concentra-
tion of 800 
 
m
 
g/ml and a hemolytic titer of 250,000 U/ml, where
one unit corresponds to the volume of C5b6 that lyses 2 
 
3
 
 10
 
7
 
guinea pig erythrocytes in 30 min at 37
 
8
 
C in the presence of 2 
 
m
 
l
EDTA human serum to a final volume of 250 
 
m
 
l.
 
Preparation of iTCC.
 
The inactive terminal C complex was
obtained by mixing C5b6 (3 
 
m
 
g), C7 (1 
 
m
 
g), C8 (1.5 
 
m
 
g), and
C9 (4 
 
m
 
g) in PBS to a final volume of 50 
 
m
 
l. The concentration
of C7 was chosen to be in slight excess of the amount required to
fully inactivate the hemolytic activity of C5b6 when mixed with
this complex for 10 min at 37
 
8
 
C before the addition of guinea pig
erythrocytes and EDTA serum (20). C8 was present in the mix-
ture in an equimolar ratio to C7, and C9 was added in large ex-
cess to favor the polymerization of this component during the as-
sembly of iTCC. The formation of complex was followed by
ELISA using solid phase–bound goat IgG anti-C5 (1/1,000) that
was incubated first with purified C5b6 (300 ng) for 1 h at 37
 
8
 
C,
and, after washing, with a mixture of C7 (100 ng), C8 (150 ng)
and C9 (400 ng) in PBS for 30 min further at 37
 
8
 
C. The amount
of bound TCC was evaluated by its reaction with 1/1,000 aE11
for 1 h at room temperature (RT) followed by 1/4,000 alkaline
phosphatase-conjugated affinity-purified goat anti–mouse anti-
bodies (Sigma Chemical Co.) for 1 h at RT. After addition of
 
p
 
-nitrophenyl phosphate (1 mg/ml) in 0.1 M glycin buffer, pH
10.4, containing 0.1 mM MgCl
 
2
 
 and 0.1 mM ZnCl
 
2
 
, the enzy-
matic reaction was developed at 37
 
8
 
C and read kinetically at 405
nm using a Titertek Multiskan ELISA reader (Flow Laboratories,
Milan, Italy). The complexes were allowed to form for 30 min at
37
 
8
 
C, for an additional 2 h at RT, and then purified by fast pro-
tein liquid chromatography on a Superose 12 column. The iTCC
was also obtained by affinity chromatography on mAb aE11
bound to Protein G–agarose (Sigma Chemical Co.) and cross-
linked with dimethyl pimelimidate dihydrochloride according to
Schneider et al. (21). The bound iTCC was eluted with 4 M
guanidine-HCl in 0.1 M sodium phosphate, pH 7, dialyzed first
against 1 mM HCl, and subsequently against PBS. Protein G–aga-
rose column with bound IgG anti-C5 was used in some experi-
ments to absorb purified iTCC. Free C9 multimers were mea-
sured by ELISA using solid phase–bound mAb aE11 and goat IgG
anti-C9 labeled with biotin (19) as revealing reagent.
 
Radiolabeling of C7.
 
The Iodogen reagent (Pierce, Rockford,
IL) was used to label C7 with 
 
125
 
I following the instructions of
the manufacturer, and the unbound iodine was removed by gel
filtration through Sephadex G25 (Pharmacia Biotech) column.
The labeled C7 was still capable of interacting with C5b6 and its
specific activity was estimated to be 2 
 
3
 
 10
 
6
 
 cpm/
 
m
 
g. 
 
125
 
I-C7
was incorporated into iTCC by incubating C5b6 first with the la-
beled C component for 5 min at 37
 
8
 
C, and subsequently with
10-fold excess cold C7, C8, and C9 following the protocol re- 
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ported above for the preparation of C5b-9. The labeled complex
was purified through Superose 12 to remove unbound 
 
125
 
I-C7
and the other free terminal components.
 
Endothelial Cell Culture.
 
Human umbilical vein endothelial
cells (HUVEC) were prepared according to Jaffe et al. (22) and
cultured in wells of tissue culture plates coated with 2% endo-
toxin-free gelatin as previously described (23). The cells were kept in
culture either in endotoxin-free medium 199 (Sigma Chemical
Co.) supplemented with 20% newborn calf serum (Hyclone Labs.,
Logan, UT) or in human endothelial serum-free medium (SFM;
GIBCO BRL, Gaithersburg, MD) with fibroblast growth factor
(20 ng/ml) and epidermal growth factor (10 ng/ml).
 
ELISA on HUVEC.
 
Binding of iTCC and expression of ad-
hesion molecules on HUVEC were evaluated on cells of the first
passage grown to confluence in 96-well tissue culture plates
(Nunc, Mascia Brunelli, Milan, Italy). After three washings with
HBSS (Sigma Chemical Co.), the cells were exposed to iTCC
in HBSS containing 1% BSA to a final volume of 200 
 
m
 
l for 1 h
at 37
 
8
 
C and the bound complex was quantified as reported above.
The expression of the adhesion molecules on HUVEC was as-
sessed on cells incubated with 100 
 
m
 
l of mAb 4B9 to VCAM-1 (5
 
m
 
g/ml), mAb RR1 to ICAM-1 (5 
 
m
 
g/ml), mAb 1.2B6 to
ELAM-1 (1 
 
m
 
g/ml), and AK-6 to P-selectin (1 
 
m
 
g/ml) for 1 h at
RT. For the detection of P-selectin, the cells were fixed with 1%
paraformaldehyde in PBS for 15 min at RT in the dark before
exposure to the relevant mAb.
 
Binding Assay for 
 
125
 
I-iTCC.
 
The procedure followed to mea-
sure the binding of 
 
125
 
I-iTCC to HUVEC was similar to that de-
scribed for the immunoenzymatic assay except that the cells were
incubated with the labeled complex (
 
z
 
30,000 cpm) in HBSS
containing 1% BSA for 1 h at 37
 
8
 
C. After careful removal of the
supernatants, the cells were washed three times and finally dis-
solved in 200 
 
m
 
l of 1 M NaOH. Both unbound and cell-bound
radioactivities were counted in a gamma counter (Cobra B5005;
Packard Instruments Company, Meriden, CT) and the results
were expressed as bound 
 
125
 
I-iTCC fractions of the total amounts
of complex added.
 
Evaluation of Tissue Factor Activity.
 
A chromogenic assay based
essentially on the method published by Mulder et al. (24) was
used to measure the expression of tissue factor (TF) by endothe-
lial cells. In brief, HUVEC grown to confluence were stimulated
with iTCC or cytokines for 4–6 h and washed three times with
medium 199. The cells were then treated with 0.2 mg/ml colla-
genase (Worthington Biochemical Corp., Freehold, NJ) in PBS
(
 
z
 
30 
 
m
 
l/well) for 15 min at 37
 
8
 
C. After addition of 250 
 
m
 
l of 10
mM Hepes solution, pH 7.45, supplemented with 137 mM
NaCl, 4 mM KCl, 11 mM glucose, 2.5 mM CaCl
 
2
 
, and 0.5%
BSA to stop the enzymatic reaction, the plates were centrifuged
at 250 
 
g
 
 for 10 min and the cell supernatant was gently removed.
The cells sedimented in each well were then incubated with 25 
 
m
 
l
of 50 mM Tris buffer, pH 7.4, containing 0.2% BSA and 0.3 U/ml
of factor VII for 3 min at 37
 
8
 
C followed by 25 
 
m
 
l/well of the
same buffer supplemented with 13 mM CaCl
 
2
 
 and 0.5 U/ml of
factor X for additional 7 min at 37
 
8
 
C. The formation of factor Xa
was evaluated kinetically at 405 nm with the Titertek Multiskan
ELISA reader after the addition of 25 
 
m
 
l of the chromogenic sub-
strate S-2765 (1.87 mM in H
 
2
 
O). Optimal readings were gener-
ally obtained after an incubation of 60–90 min at 37
 
8
 
C.
 
SDS-PAGE and Western Blotting.
 
TCC was analyzed by SDS-
PAGE and immunoblotting following a procedure previously de-
scribed (19) with some modifications that included boiling of the
complex for 5 min in the sample buffer containing 6% SDS, an
electrophoretic run on a 6–10% gradient gel under nonreducing
conditions and the use of the semidry SemiPhor transfer unit
(Heifer Scientific Instruments, San Francisco, CA) for blotting.
 
Detection of mRNA for Adhesion Molecules.
 
The procedures for
RNA extraction with phenol-chloroform from cells lysed in a
guanidine thyocianate solution, the reverse transcription with ran-
dom examers in the presence of Mo-MLV reverse transcriptase
(Perkin-Elmer, Cetus, Norwalk, CT), and the PCR reaction per-
formed to obtain a semiquantitative PCR analysis have previously
been described (25). The oligonucleotides were purchased from
Duotech (Milan, Italy). The following primers were used to am-
plify the VCAM-1 gene: forward 5
 
9
 
 CAAGTCTACATAT-
CACCCAAGA 3
 
9
 
, from position 758 to position 779, and back
5
 
9
 
 GGAACCTTGCAGCTTACAGTGACAGAGCTCCC 3
 
9
 
,
from position 1081 to position 1112, according to the published
cDNA (26). The primers employed to amplify the ELAM-1 gene
were the following: forward 5
 
9
 
 GGTAGGAACCCAGAAAC-
CTCTGA 3
 
9
 
 from position 365 to position 387 and back 5
 
9
 
TTCCCAGATGAGGTACACTGAAG 3
 
9
 
, from position 985 to
position 967 according to the published cDNA (27).
The amplified products were run through a 1% agarose gel
containing ethidium bromide and transferred onto a nylon filter
(Zeta-Probe; Bio Rad Labs., Hercules, CA). Hybridization was
carried out according to standard protocols (28) with oligonucle-
otides that had been labeled in a 25-
 
m
 
l reaction mixture contain-
ing 50 ng oligo in kinase buffer with 
 
32
 
P
 
g
 
ATP (6,000 Ci/mmol;
DuPont New England Nuclear, Boston, MA) in the presence of
T4 kinase (Boehringer Mannheim GmbH, Mannheim, Germany)
and then passed through Quick Spin Columns (Boehringer Mann-
heim, GmbH).
The “internal” oligonucleotide to detect VCAM-1 has the fol-
lowing sequence: 5
 
9 
 
TTCTGTGAATCCATCCACAAAGC 3
 
9
 
,
from position 789 to position 811 of the published cDNA se-
quence (26). The sequence of the internal oligonucleotide to re-
veal ELAM-1 was as follows: 5
 
9
 
 GAGCATGGAAGCCTGGTT-
TGCAG 3
 
9
 
, from position 675 to position 697 of the published
cDNA (27).
The human 
 
b
 
-actin gene was amplified from 5 
 
m
 
l of the same
reverse transcribed mixture using the following primers: forward
5
 
9
 
 AAGATGACCCAGATCATGTTTGAG 3
 
9
 
 and back 5
 
9
 
 GGA-
GCAATGATCTTGATCTTC 3
 
9
 
 as previously reported (25, 28).
 
Statistical Analysis.
 
Data are reported as mean 
 
6 SEM. The
Student’s t test was used to compare two groups of data.
Results
Characterization of iTCC. Mixing C5b6 with the remain-
ing late components in the proportion reported in Materials
and Methods resulted in the formation of TCC that rapidly
lost hemolytic activity. The results presented in Fig. 1
clearly show that lysis induced by the complex dropped to
z25% of the control value in about 30 s from initiation of
the complex formation, and was negligible within 1 min of
incubation. By contrast, the time required for the stabiliza-
tion of the complex was somewhat longer. Thus, the ex-
pression of C9 neoantigen, followed as a marker of TCC
formation, though already apparent 1 min after mixing the
C reagents, progressively increased with time reaching its
highest value after 30 min of incubation (Fig. 1). As ex-
pected, all the terminal C components, including the C9
dimer, were detected when iTCC was examined by SDS-
PAGE and Western blotting (Fig. 2). Free C9 multimers1622 Proinflammatory and Procoagulant Effects of Inactive Terminal C Complex
could not be detected in the unretained fraction of iTCC
(1 mg) adsorbed onto IgG anti-C5 bound to protein G–aga-
rose when tested by ELISA using solid phase bound mAb
aE11 and biotin-labeled goat anti-C9 as revealing reagent
with a sensitivity limit of 1–2 ng/ml.
Binding of iTCC to HUVEC. The interaction of iTCC
with the endothelial cells was analyzed with mAb aE11 which
recognizes a C9 neoantigen expressed by the complex. The
data presented in Fig. 3 A indicate that the amount of
iTCC bound to HUVEC was related to the dose of iTCC
offered up to 5 mg/ml and showed the tendency to reach a
plateau with higher concentrations of the complex. The
specificity of these findings was confirmed by the negative
results obtained when C5b6 was added to HUVEC cul-
tured in TC199 supplemented with 10% C7-depleted se-
rum or when the cells were exposed to the same amount of
purified C9 used for the preparation of iTCC (data not
shown). The experiments performed with 125I-iTCC essen-
tially confirmed the results obtained with ELISA and, more-
over, showed that the bound complex represents z1% of
the total radioligand added (Fig 3 B).
To evaluate the kinetic of binding of the inactive com-
plex to HUVEC, the cells were incubated with iTCC and
washed at various time intervals to measure the amount of
bound complex. The data presented in Fig. 4 indicate that
approximately half of the total amount of bound complex
could be detected on the surface of EC after 15 min of in-
cubation.
Analysis of iTCC binding to HUVEC in the presence of
polyclonal IgG antibodies directed against the terminal
components revealed a marked inhibitory effect of the anti-
C9 antibodies, whereas the anti-C6 and the anti-C7 had only
a marginal inhibitory activity and the other antibodies were
ineffective (Fig. 5). The inhibitory effect induced by goat
anti-C9 could also be obtained using rabbit IgG anti-C9.
Expression of Adhesion Molecules on HUVEC Induced by
iTCC. Exposure of HUVEC to iTCC resulted in upreg-
ulation of the cell expression of VCAM-1, ICAM-1, and
ELAM-1 (Fig. 6). This effect was dose related and was evi-
dent in cells stimulated with 5 mg/ml of iTCC, though the
complex was already active in lower amounts. The com-
plex purified by affinity chromatography with mAb aE11
proved to be more effective than iTCC obtained by gel fil-
tration on Superose 12 inasmuch as it induced a similar ex-
pression of adhesion molecules at half the concentration (data
Figure 1. Kinetic of assembly and functional decay of iTCC. 50 ml ali-
quots of a 1-ml mixture containing C5b6 (3 mg), C7 (1 mg), C8 (1.5 mg)
and C9 (4 mg) in PBS were tested hemolytically at various time intervals
on guinea pig erythrocytes (d). The assembly of iTCC was measured ki-
netically by ELISA (s). Details of the assays are given in Materials and
Methods. GPE, guinea pig erythrocytes.
Figure 2. SDS-PAGE analysis of puri-
fied iTCC. A total amount of 2 mg of
iTCC was applied to the gel and run
under nonreducing conditions in a 6–10%
gradient gel. The position of the bands
and their reference to the individual
components were checked in parallel by
Western blot using specific antisera.
Figure 3. Binding of iTCC to
HUVEC. HUVEC monolayers
were incubated with increasing
concentrations of either cold
iTCC (A) or 125I-iTCC (B) in
HBSS containing 1% BSA to a
final volume of 200 ml. After 1 h
of incubation at 378C, the
amount of bound iTCC was
measured by ELISA using mAb
aE11 as revealing reagent or by
counting the cell-bound radioac-
tivity. Binding of 125I-iTCC was
inhibited when mixed with 10
M–fold excess of cold iTCC.
Figure 4. Kinetic of iTCC
binding to HUVEC. EC mono-
layers were incubated at 378C
with 5 mg/ml of iTCC for vari-
ous lengths of time and the
amount of bound complex was
measured by ELISA as indicated
in Fig. 3.1623 Tedesco et al.
not shown). Kinetic experiments performed with an opti-
mal amount of iTCC (5 mg/ml) showed that the expression
of the three adhesion molecules on the surface of endothe-
lial cells was maximal 6 h after addition of the complex and
persisted up to 24 h in the case of ICAM-1 and VCAM-1,
whereas the expression of ELAM-1 decreased to back-
ground level after 12 h of incubation (Fig. 7). Exposure of
HUVEC to the C complex for 1 h followed by washing
was sufficient to induce the expression of the adhesion
molecules after 6 h of incubation, but the amount of de-
tectable molecules was threefold higher in the continuous
presence of the stimulus (data not shown). The upregula-
tion of adhesion molecules obtained with iTCC was signif-
icantly inhibited by the addition of goat IgG anti-C9 to the
incubation mixture, but could not be reproduced with C9
alone (5 mg/ml), and the extent of the increased expression
varied between one third and one half that induced by
other well-known stimulating agents, such as IL-1a, TNF-a,
and LPS (Fig. 8). The stimulating activity of the complex
was unaffected by the presence of polymyxin B (5 mg/ml) and
was totally lost when iTCC was boiled for 10 min (data not
shown).
The complex was also examined for its ability to stimu-
late the expression of P-selectin previously shown to be
rapidly induced by sublytic amounts of MAC (7). Fig. 9
shows that iTCC has a negligible effect on the expression
Figure 5. Inhibition of iTCC binding to HUVEC by antibodies to the
terminal C components. EC were incubated with 125I-iTCC (300 pM) in
the presence of goat antibodies to the individual late components (100 mg).
After 1 h incubation at 378C, the cells were washed and the radioactivity
was counted. The results are presented as mean 6 SEM of percent values
of the control obtained with normal goat IgG in three different experi-
ments.
Figure 6. Dose response curve of iTCC-induced upregulation of
VCAM-1, ILAM-1, and ELAM-1 molecules on HUVEC. EC were ex-
posed to increasing concentrations of iTCC in 200 ml of complete SFM
containing 1% BSA and tested by ELISA for the expression VCAM-1 and
ICAM-1 after an overnight incubation and for the expression of ELAM-1
after 5 h of incubation.
Figure 7. Time courses of in-
duction of ELAM-1, ICAM-1,
and VCAM-1 expression by
HUVEC exposed to iTCC (5
mg/ml) or TNF-a (200 U/ml)
in complete SFM containing 1%
BSA. Cells were harvested at the
indicated times and examined for
adhesion molecule expression by
ELISA.
Figure 8. Comparison of the stimulating effect of iTCC (5 mg/ml),
IL-1a (10 U/ml), TNF-a (200 U/ml), and LPS (1 mg/ml) in 200 ml of
complete SFM containing 1% BSA. The experimental conditions are sim-
ilar to those used for Fig. 6. Data showing inhibition of the stimulatory
effect of iTCC by anti-C9 and the effect of C9 are also reported. The re-
sults are presented as mean 6 SEM of eight different experiments. *P ,0.05
versus control; NS, not significant.1624 Proinflammatory and Procoagulant Effects of Inactive Terminal C Complex
of P-selectin, unlike active TCC and histamine used as
positive controls.
RNA Messages for ELAM-1 and VCAM-1 in iTCC-Treated
HUVEC. To confirm the results observed at the protein
level, HUVEC activated by iTCC and, for comparison, by
IL-1a and LPS or control cells, were examined for the expres-
sion of RNA messages for ELAM-1 and VCAM-1 using
the semiquantitative reverse transcriptase PCR (RT-PCR)
reported in Materials and Methods. The analysis was per-
formed on the same RNA preparations purified from an
equal number of cells, that had been stimulated under the
same experimental conditions and then lysed in an equal
volume of guanidine solution before being processed for
the isolation of RNA. The results of ELAM-1 (A) and
VCAM-1 (B) amplification presented in Fig. 10 show a
clear increase in the messages for both molecules in cells
exposed to iTCC, IL-1a, or LPS when compared to the
pattern of the unstimulated cells, despite a comparable
amount of b-actin RNA in all samples. In addition, a pre-
viously reported alternatively spliced form of VCAM-1 of
lower molecular size (355 bp; reference 29) can be recog-
nized in cells stimulated by iTCC, IL-1a, and LPS.
Expression of TF Activity on HUVEC Induced by iTCC.
The ability of iTCC to induce endothelial TF activity was
investigated by exposing HUVEC to the amount of com-
plex (5 mg/ml) that promotes expression of the adhesion
molecules. In a time-course experiment we found that TF
activity was hardly detectable 1 h after addition of iTCC,
but gradually increased starting after 2 h of incubation
reaching the highest level after 6 h (Fig. 11). The stimulat-
ing effect of the C complex was approximately one half to
one third lower than that obtained with optimal concentra-
tions of LPS, TNF-a, and IL-1a, used as positive controls,
and was blocked by the presence of IgG anti-C9 (Fig. 12).
Additional experiments showed that TF activity induced
by iTCC was associated with the expression of a molecule
that was inhibited by cycloheximide (10 mg/ml) and was
functionally neutralized by an mAb directed against the TF
protein (data not shown).
Discussion
The data presented in this study show that iTCC binds
to HUVEC and stimulates the expression of adhesion mol-
ecules and TF, though is unable to insert into the cell
membrane. In preparing iTCC, we took advantage of the
short half-life of less than 1 min required for TCC to inter-
act as MAC with bystander cells (13, 14). For this reason,
the inactive complex was prepared by incubating the mix-
ture of C5b6 and the remaining terminal C components
for at least 30 min at 378C and for an additional 2 h at RT.
TCC, prepared under these conditions, was unable to lyse
guinea pig erythrocytes, which represent a highly suscepti-
ble target for lysis induced by human C complex, and had
no cytolytic effect on HUVEC allowing normal survival of
these cells in culture.
Figure 9. Expression of P-selectin on HUVEC stimulated with active
and inactive TCC and with histamine. The active and inactive TCC were
prepared using the same concentrations of C components (see Materials
and Methods) and differed only because the C components were mixed
in the presence of HUVEC to form the active complex and were prein-
cubated in their absence to obtain iTCC. Histamine was added in con-
centration of 250 mM. The cells were incubated with the various reagents
for 10 min at 378C and the amount of P-selectin expressed on HUVEC
was measured by ELISA after fixing the cells with paraformaldehyde. The
results represent the mean 6 SEM of four different experiments. *P
,0.05 versus control; NS, not significant.
Figure 10. Semiquantitative
RT-PCR analysis of the ELAM-1
(A) and VCAM-1 (B) genes and,
for comparison, of the b-actin
gene. EC (6 3 104) incubated
under the various experimental
conditions for 2 h at 378C were
lysed in 300 ml of guanidine so-
lution and then processed for
RT-PCR analysis. (lane 1) Con-
trol cells; (lane 2) cells treated
with 10 U/ml IL-1a; (lane 3) 1
mg/ml LPS; and (lane 4) 5 mg/ml
iTCC. Sterile distilled water sub-
stituting for RNA was similarly
processed as a negative control
(lane  5).
Figure 11. Time courses of induction of TF expression by HUVEC
exposed to iTCC (5 mg/ml) or LPS (1 mg/ml). Cells were harvested
at the indicated times and examined for TF expression by a chromogenic
assay.1625 Tedesco et al.
Binding of iTCC to HUVEC was supported by two sets
of data. First, the presence of the complex on the cell sur-
face was revealed by ELISA using mAb aE11, which recog-
nizes only C9 assembled in the TCC, but not the native
molecule. The specificity of this finding was confirmed by
the observation that aE11 did not react with cells treated
with a mixture of C5b6- and C7-depleted serum, a condi-
tion that does not allow assembly of the complex. Further
evidence was obtained with experiments performed with
125I-labeled complex, that showed binding of z1% of iTCC
to HUVEC.
Based on the results of inhibition experiments with poly-
clonal antibodies against the terminal C components, we con-
cluded that C9 is the component of the complex that
mostly contributes to its interaction with the EC, since the
antibody to C9 proved to be the only one to exert a strong
inhibitory effect. This finding was not surprising since C9
undergoes a process of polymerization when it is incorpo-
rated into the soluble TCC in the absence of vitronectin
and clusterin, thus becoming its major constituent with
an average number of seven molecules per complex (30).
Whether binding of iTCC to endothelial cells is receptor
mediated can not be established with the present data and
is currently under investigation. However, Wang et al.
(14) have recently shown that the inactive form of C5b67
bound to erythrocytes is released from the surface of
trypsin-treated cells in higher amounts than the hemolytic-
ally active complex suggesting a different type of interac-
tion of the active and inactive complexes with the cell
membrane.
The observation that HUVEC exposed to iTCC ex-
pressed ELAM-1, ICAM-1, and VCAM-1 clearly indicates
that binding of the inactive complex to these cells has im-
portant biological consequences, one of which is to pro-
mote the inflammatory process. In this respect, iTCC dif-
fers from the cytolytically active complex since Kilgore et al.
(10) recently failed to induce upregulation of these adhe-
sion molecules on HUVEC with MAC alone, despite the
fact that they used a concentration of complex similar to that
of iTCC used in this study. The only effect of MAC that they
were able to see was an enhancement of TNF-a–induced
cell activation.
The expression of ELAM-1, ICAM-1, and VCAM-1 on
HUVEC stimulated by iTCC followed a kinetic pattern
essentially similar to that observed by other groups with
TNF-a and IL-1a (18, 27, 31) and in this study with
TNF-a, although the latter had a tendency to induce a
more rapid and greater response. The lag phase of 4 to 6 h
needed to reveal a clear expression of the three molecules
on HUVEC after the addition of iTCC clearly indicates
that protein synthesis was required, as has already been shown
for other inducers. This is confirmed by the finding that iTCC
induced an increase in the corresponding RNA messages that
preceded the expression of the molecules on the cell surface.
Our major concern was to exclude the possibility that
LPS contaminating the C reagents might be responsible for
cell activation, but this was ruled out by the findings that
the C complex was still effective in the presence of poly-
myxin B and totally lost its activity after boiling. Further
evidence in favor of the specificity of action of iTCC is
provided by the data showing inhibition of the stimulatory
activity of the C complex by antibodies to C9. Of course,
this observation does not exclude the fact that the effect of
iTCC can be mediated by soluble C9 or some forms of C9
multimers present in the iTCC preparation, although our
failure to detect C9 polymers by ELISA and to induce cell
stimulation with native C9 makes the contribution of free
C9 highly unlikely. The inability of iTCC to stimulate the
rapid expression of P-selectin on HUVEC contrasts with
the appearance of this adhesion molecule on the surface of
MAC-treated EC originally reported by Hattori et al. (7)
and confirmed in the present study. These data again em-
phasize the differences in the biological effects elicited by
the two complexes on HUVEC.
Exposure of endothelial cells to iTCC was sufficient to
initiate the extrinsic pathway of coagulation just like treat-
ment of these cells with LPS and other cytokines. The
molecule on HUVEC responsible for this activity is recog-
nized by an mAb that is able to block the TF-dependent
formation of factor Xa and the consequent hydrolysis of the
chromogenic substrate used in our assay system. The in-
duction of TF in endothelium by iTCC requires protein
synthesis since the expression of the molecule on the cell
surface can be inhibited by the presence of cycloheximide
in the incubation mixture.
Saadi et al. (32) have recently shown that MAC stimu-
lates synthesis of TF in porcine EC exposed to human or
rabbit antibodies and human C. This is a model system for
xenotransplants and is basically different from our experi-
mental model not only because it evaluates the effect of a
cytolytically active complex, though tested in sublytic
amounts, but also because the source of MAC is heterolo-
gous with respect to the target cells. Under these condi-
Figure 12. Expression of TF on HUVEC stimulated with iTCC, alone
or in the presence of anti-C9, LPS, TNF-a, or IL-1a. The cells were in-
cubated for 5 h with the different reagents used at the same concentra-
tions reported in the legend to Fig. 8 and tested for the amount of TF ex-
pressed by a chromogenic assay. The results represent the mean 6 SEM
of four different experiments. *P ,0.05 versus control; NS, not signifi-
cant.1626 Proinflammatory and Procoagulant Effects of Inactive Terminal C Complex
tions, MAC operates in the absence of homologous restric-
tion imposed by CD59, which is present on the surface of
EC (33). In addition, in their model TF is expressed over a
period of 16–42 h and requires the release of IL-1a as an
intermediate step, whereas in our system the expression of
TF is observed in z4–6 h. Despite these differences, how-
ever, all together these data provide experimental support
for the contribution of both cytolytically active and inac-
tive TCC to favor accumulation of fibrin deposits and for-
mation of thrombi in vessels in the course of immune-
mediated disorders associated with persistent and sustained
C activation.
In conclusion, a novel role has been recognized for iTCC
that has long been considered an irrelevant by-product of
the C activation cascade. The serum levels of the inactive
complex reported in various clinical disorders (34–36) are
compatible with the concentrations that were found to be
effective in this study. It is quite possible, however, that
under conditions of massive C activation, high amounts of
iTCC can be formed in vivo, some of which escapes con-
trol by vitronectin and clusterin, and that a great propor-
tion of this complex rapidly disappears from the circulation
(37) interacting with EC. Such a possibility is suggested by
the mild clinical course of meningococcal disease observed
in patients with inherited deficiencies of the terminal com-
ponents, who experience less frequently septic shock, intra-
vascular coagulation, and purpura than C-sufficient patients
(38, 39).
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